

OncoViews on DLBCL: CAR T-Cells Vs Bispecifics

14 May 2024

Tentative Agenda

Finalization & confirmation pendant.

Time Zone: Central European Time

<u>Time</u>	<u>Topic</u>	<u>Speaker</u>
17:00	Welcome & introduction by host	M. Pirosa
17:05	The case for CAR: why CAR T-cells can excel DLBCL care	F. Simonetta
17:30	The case for Bispecifics: bispecific therapy can provide a dynamic approach to DLBCL management	T. Zenz
17:55	Which holds a greater promise for transforming DLBCL treatment: CAR T-Cells or Bispecifics? <i>Debate and open discussion</i>	All panelists
18:30	Closing remarks	M. Pirosa

Speakers & Discussants:

- **Maria Pirosa** Ente Ospedaliero Cantonale (EOC), Switzerland
- **Federico Simonetta** University of Geneva, Switzerland
- **Thorsten Zenz** University Hospital Zurich, Switzerland